Lawsuit blames teen’s death during flight on defibrillator issue, lack of training

In June 2022, a passenger on an American Airlines flight from Honduras to Miami died after going into cardiac arrest and losing consciousness. The flight’s crew did attempt to use an automatic external defibrillator (AED) to revive the deceased—a teenager named Kevin Greenidge—but the AED did not work.

Greenidge’s family has now filed a lawsuit blaming American Airlines for the incident, according to a report from The Dallas Morning News. The lawsuit points to two primary issues: the AED not being properly charged, and the American Airlines crew not being trained to handle such situations.

The Dallas Morning News noted in its coverage that American Airlines actually has a long history with AEDs.

“A corporate medical doctor that worked at American Airlines from 1994 to 2002 convinced the carrier to keep defibrillators on board,” according to the report. “David McKenas worked with American and its then-CEO Bob Crandall to make it the first U.S. airline to put defibrillators on board. On Feb. 18, 1998, the first life was saved by a defibrillator on an American Airlines flight.”

American Airlines has not yet commented publicly on the family's accusations. 

Click the link below for more details:

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.